Evidence map›Paper›PMID 30937292›Full record

ArticleProstate international2019

Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy.

Ayako Ohtaka, Hiroaki Aoki, Masayoshi Nagata, Mayuko Kanayama, Fumitaka Shimizu, Hisamitsu Ide, Akira Tsujimura, Shigeo Horie

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis.European journal of nuclear medicine and molecular imaging · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ayako OhtakaDepartment of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
Hiroaki AokiDepartment of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
Masayoshi NagataDepartment of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
Mayuko KanayamaDepartment of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
Fumitaka ShimizuDepartment of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
Hisamitsu IdeDepartment of Urology, School of Medicine, Teikyo University, Tokyo, Japan.
Akira TsujimuraDepartment of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
Shigeo HorieDepartment of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
Juntendo University · JPTeikyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSarcopenia is a geriatric syndrome that is characterized by the gradual muscle loss and frailty in the elderly. Meanwhile, the prevalence of prostate cancer is on the rise worldwide. Mainstay treatments for metastatic prostate cancer are androgen-deprivation therapy and taxane-based chemotherapy. Owing to the indolent nature of prostate cancer, these treatments tend to be long-lasting, giving rise to the problem of tolerance to the treatments. Especially given the fact that long-term chemotherapy is closely associated with muscle loss, we aimed to elucidate the correlation between chemotherapy and sarcopenia in the clinical setting. MATERIALS AND

methodsThis study was a retrospective study. Participants with castration-resistant prostate cancer were recruited from November 2009 to September 2015.Participants were recruited at two hospitals, Juntendo and Teikyo University Hospital, Tokyo, Japan.Participants were 77 Japanese males with castration-resistant prostate cancer who underwent docetaxel chemotherapy.Sarcopenia was defined as L3-psoas muscle index < 5.7 cm

resultsOut of 77 patients, 26 patients (34%) were diagnosed as sarcopenia. Analysis showed that sarcopenia is independently associated with mortality risk (hazards ratio = 2.74,

conclusionSarcopenia is an independent predictive factor for a poor tolerance to docetaxel treatment. Given that cessation of the treatment leads to death from the disease, our study identified sarcopenia as an independent factor that raises mortality risk.

Indexed as

Castration-resistant prostate cancerDocetaxelSarcopenia

Identifiers

PMID30937292
PMCPMC6424678
OpenAlexW2802320119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.